NORTHWEST BIOTHERAPEUTICS INC Net Income (Loss) Available to Common Stockholders, Diluted
NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$62.60 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-05.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-03-05
- NORTHWEST BIOTHERAPEUTICS INC net income (loss) available to common stockholders, diluted for the quarter ending 2022-12-31 was -$28.30M.
- NORTHWEST BIOTHERAPEUTICS INC net income (loss) available to common stockholders, diluted for the quarter ending 2022-09-30 was -$32.85M.
- NORTHWEST BIOTHERAPEUTICS INC net income (loss) available to common stockholders, diluted for the quarter ending 2022-06-30 was -$29.67M.
- NORTHWEST BIOTHERAPEUTICS INC net income (loss) available to common stockholders, diluted for the quarter ending 2021-12-31 was -$25.45M.
- NORTHWEST BIOTHERAPEUTICS INC net income (loss) available to common stockholders, diluted for fiscal 2023 was -$62.60M.
- NORTHWEST BIOTHERAPEUTICS INC net income (loss) available to common stockholders, diluted for fiscal 2022 was -$105.03M.
- NORTHWEST BIOTHERAPEUTICS INC net income (loss) available to common stockholders, diluted for fiscal 2021 was -$60.22M.
- NORTHWEST BIOTHERAPEUTICS INC net income (loss) available to common stockholders, diluted for fiscal 2020 was -$529.82M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | -$62.60M 10-K · filed 2024-03-05 | ||||||
| 2022-12-31 | -$28.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$61.15M derived: sum of 2 quarters · filed 2024-03-05 | -$90.82M derived: sum of 3 quarters · filed 2024-03-05 | -$105.03M 10-K · filed 2024-03-05 | |||
| 2022-09-30 | -$32.85M 10-Q · filed 2022-11-09 | -$62.52M derived: sum of 2 quarters · filed 2022-11-09 | -$76.73M 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | -$29.67M 10-Q · filed 2022-08-09 | -$43.88M 10-Q · filed 2022-08-09 | |||||
| 2021-12-31 | -$25.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$38.53M derived: sum of 2 quarters · filed 2024-03-05 | -$51.63M derived: sum of 3 quarters · filed 2024-03-05 | -$60.22M 10-K · filed 2024-03-05 | |||
| 2021-09-30 | -$13.09M 10-Q · filed 2022-11-09 | -$12.95M 10-Q · filed 2021-11-15 | -$26.18M derived: sum of 2 quarters · filed 2022-11-09 | -$34.78M 10-Q · filed 2022-11-09 | -$47.73M 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | -$13.09M 10-Q · filed 2022-08-09 | -$34.78M 10-Q · filed 2022-08-09 | |||||
| 2020-12-31 | -$280.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$474.39M derived: sum of 2 quarters · filed 2023-02-28 | -$532.45M derived: sum of 3 quarters · filed 2023-02-28 | -$529.82M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | -$194.10M 10-Q · filed 2021-11-15 | -$252.15M derived: sum of 2 quarters · filed 2021-11-15 | -$249.52M 10-Q · filed 2021-11-15 | -$243.09M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | -$58.05M 10-Q · filed 2021-08-16 | -$57.95M 10-Q · filed 2020-08-10 | -$55.43M 10-Q · filed 2021-08-16 | -$55.23M 10-Q · filed 2020-08-10 | -$49.00M derived: sum of 3 quarters · filed 2022-03-01 | -$55.24M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $2.90M 10-Q · filed 2020-06-24 | $9.06M derived: sum of 2 quarters · filed 2022-03-01 | $2.81M derived: sum of 3 quarters · filed 2022-03-01 | $3.16M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $6.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$85.00K derived: sum of 2 quarters · filed 2022-03-01 | $259.00K derived: sum of 3 quarters · filed 2022-03-01 | -$20.81M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | -$6.24M 10-Q · filed 2019-11-12 | -$5.90M derived: sum of 2 quarters · filed 2020-08-10 | -$26.97M 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $344.00K 10-Q · filed 2020-08-10 | -$20.73M 10-Q · filed 2020-08-10 | |||||
| 2019-03-31 | -$20.95M 10-Q · filed 2020-06-24 | ||||||
| 2018-09-30 | $11.02M 10-Q · filed 2019-11-12 | -$13.69M derived: sum of 2 quarters · filed 2019-11-12 | -$47.91M 10-Q · filed 2019-11-12 | ||||
| 2018-06-30 | -$24.71M 10-Q · filed 2019-08-09 | -$56.31M 10-Q · filed 2019-08-09 | |||||
| 2017-09-30 | -$23.27M 10-Q · filed 2018-11-16 | -$46.14M 10-Q · filed 2018-11-16 | |||||
| 2016-09-30 | -$32.23M 10-Q · filed 2016-11-10 | -$55.15M 10-Q · filed 2016-11-10 | |||||
| 2015-09-30 | $22.69M 10-Q · filed 2016-11-10 | -$90.66M 10-Q · filed 2016-11-10 | |||||
| 2014-09-30 | -$21.04M 10-Q · filed 2015-11-09 | -$92.95M 10-Q · filed 2015-11-09 |